Skip to main content
. Author manuscript; available in PMC: 2021 Aug 5.
Published in final edited form as: J Am Coll Cardiol. 2020 Nov 2;76(21):2527–2564. doi: 10.1016/j.jacc.2020.07.023
Reviewer Representation Employment Consultant Speakers Bureau Ownership/Partnership/Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness
Siqin Kye Ye ACC/AHA TFPM Lead Reviewer Center for Behavioral Cardiovascular Health–Assistant Professor of Medicine; Cardiology Inpatient Consultation Service–Director; Columbia Doctors–Associate Chief Medical Officer None None None None None None
John L. Jefferies Official ACC University of Tennessee Health Science Center–Jay M. Sullivan Distinguished Chair in Cardiovascular Medicine, Chief of Cardiology
  • Abbott*

  • Amicus

  • AstraZeneca

  • Bayer*

  • CHF Solutions*

  • Medtronic*

  • Myokardia

  • Protalix

  • Sanofi Genzyme*

  • Stealth Biotherapeutic

  • Ambry Genetics

  • Pfizer

  • Sanofi Genzyme*

None None None None
Pam Peterson Official ACC University of Colorado Anschutz Medical Campus–Professor of Medicine, Denver Health Medical Center None None None None
Howard J. Eisen Official AHA Penn State College of Medicine–Chief, Division of Cardiology None None None None None None
Janet N. Scheel Official AHA Washington University School of Medicine/St. Louis Children’s Hospital–Professor of Pediatrics and Pediatric Cardiologist None None None None None None
Robert John Mentz Official HFSA Duke University School of Medicine–Associate Professor of Medicine, Associate Professor in Population Health Sciences, Member in the Duke Clinical Research Institute
  • Abbott

  • Akros

  • Amgen*

  • Bayer*

  • Boehringer Ingelheim*

  • HeartWare

  • Janssen

  • Luitpold Pharmaceutical

  • Merck*

  • Novartis*

  • Sanofi-Aventis

  • Thoratec

None None
  • American Regent

  • Amgen

  • AstraZeneca

  • Bayer

  • Bristol-Myers Squibb

  • Gilead Sciences

  • GlaxoSmithKline

  • Luitpold Pharmaceuticals

  • Medtronic

  • Merck

  • Novartis

  • Otsuka Pharmaceutical Co.

  • Resmed

  • Vifor

None None
Mary Norine Walsh Content ACC St. Vincent Heart Center of Indiana–Medical Director Heart Failure and Cardiac Transplantation None None None None
  • EBR Systems

  • Thoratec

  • Uppsala University

None
Eldrin F. Lewis Content AHA Brigham and Women’s Hospital–Associate Physician; Harvard Medical School–Associate Professor of Medicine
  • Amgen

  • DalCor*

  • Novartis*

None None
  • Amgen*

  • Merck*

  • NIH (NHLBI)*

  • Novartis*

None
  • Defendant, Sudden death, 2019

Nancy M. Albert Content ACC/AHA Research and Innovation, Cleveland Clinic Health System & CNS/Kaufman Center for Heart Failure, Heart, Vascular & Thoracic Institute–Associate Chief Nursing Officer
  • AstraZeneca

  • Boston Scientific

  • Novartis

  • Novartis

None None
Sana M. Al-Khatib Content ACC/AHA Duke University School of Medicine–Professor of Medicine, Member in the Duke Clinical Research Institute
  • Medtronic

  • Milestone Pharmaceuticals

None None
  • Abbott

  • FDA*

  • Medtronic

  • NHLBI*

  • PCORI*

  • Abbott

  • AHA*

  • Bristol-Myers Squibb

  • Medtronic

  • Pfizer

  • Plaintiff, patient died of VT due to QT-prolonging meds, 2018

  • Plaintiff, SCD, 2018

  • Plaintiff, SCD Prevention, 2018

Anita Deswal Content ACC/AHA Baylor College of Medicine–Chief, Medicine-Cardiology, Michael E. DeBakey VA Medical Center & Baylor College of Medicine; Professor, Medicine-Cardiology, Winters Center for Heart Failure Research None None None
  • ACC/AHA

  • HFSA

None
Mona Fiuzat Content ACC/AHA Duke University School of Medicine–Adjunct Associate Professor, Department of Medicine None None None
  • Roche*

None None
Adrian F. Hernandez Content ACC/AHA Duke University School of Medicine–Vice Dean for Clinical Research
  • Amgen

  • AstraZeneca

  • Bayer

  • BioFourmis

  • Boehringer Ingelheim

  • Boston Scientific*

  • Merck

  • Novartis*

  • Pfizer

  • Relypsa

  • Sanofi-Aventis

  • Xogenex

None None
  • American Regent

  • AstraZeneca*

  • Daiichi Sankyo

  • Eidos (DSMB)

  • Genentech

  • GlaxoSmithKline*

  • Luitpold Pharmaceuticals

  • NIH

  • Merck

  • Novartis*

  • PCORI

  • Verily*

  • Defendant, patent dispute, 2019

J. Herb Patterson Content ACC/AHA UNC Eshelman School of Pharmacy–Interim Chair, Division of Pharmacotherapy and Experimental Therapeutics, Professor of Pharmacy, Research Professor of Medicine
  • Novartis*

None None None None
Andrea Russo Content ACC/AHA Cooper Medical School of Rowan University–Professor of Medicine and Director; Cardiac Electrophysiology and Arrhythmia Services–Director; Cardiovascular Research Cooper University Hospital Dorrance #393–Program Director, Clinical Cardiac Electrophysiology Fellowship None None None None
  • Apple

  • Boehringer Ingelheim

  • Boston Scientific

  • Kaestra

  • MediLynx

  • UpToDate

None
Paul Varosy Content ACC/AHA VA Eastern Colorado Health Care System–Director of Cardiac Electrophysiology None None None
  • Research Grant Funding: PI Career Development Award, Co-Investigator VA Merit Review Grant*

None

This table represents all relationships of reviewers with industry and other entities that were reported at the time of peer review, including those not deemed to be relevant to this document, at the time this document was under review. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review. Please refer to http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees.

*

Significant (greater than $5,000) relationship.

No financial relationship.

This disclosure was entered under the Clinical Trial Enroller category in the ACC’s disclosure system.

ACC indicates American College of Cardiology; AHA, American Heart Association; CNS, Clinical Nurse Specialist; DSMB, Data Safety and Monitoring Board; FDA, U. S. Food and Drug Administration; HFSA, Heart Failure Society of America; NHLBI, National Heart, Lung, and Blood Institute; NIH, National Institutes of Health; PCORI, Patient-Centered Outcomes Research Institute; PI, principal investigator; SCD, sudden cardiac death; TFPM, Task Force on Performance Measures; UNC, University of North Carolina; VA, Veterans Administration; and VT, ventricular tachycardia.